These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 950467)
1. In vitro activation of mouse macrophages by rat lymphocyte mediators. Fidler IJ; Darnell JH; Budmen MB J Immunol; 1976 Aug; 117(2):666-73. PubMed ID: 950467 [TBL] [Abstract][Full Text] [Related]
2. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. Fidler IJ; Darnell JH; Budmen MB Cancer Res; 1976 Oct; 36(10):3608-15. PubMed ID: 953987 [TBL] [Abstract][Full Text] [Related]
3. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages. Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520 [TBL] [Abstract][Full Text] [Related]
4. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Poste G; Kirsh R; Fogler WE; Fidler IJ Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777 [TBL] [Abstract][Full Text] [Related]
5. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633 [TBL] [Abstract][Full Text] [Related]
6. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. Sone S; Fidler IJ J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635 [TBL] [Abstract][Full Text] [Related]
7. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. Sone S; Poste G; Fidler IJ J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253 [TBL] [Abstract][Full Text] [Related]
8. Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. Piessens WF; Churchill WH; David J Immunol; 1975 Jan; 114(1 Pt 2):293-9. PubMed ID: 163856 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Fidler IJ; Bucana C Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034 [TBL] [Abstract][Full Text] [Related]
10. Regulatory role of humoral factors released by macrophages in rat lymphocyte reactivity in vitro. I. Influence of humoral factors released by sensitized peritoneal macrophages on normal lymphocyte reactivity. Brajczewska-Fischer W; Ryzewska AG Arch Immunol Ther Exp (Warsz); 1980; 28(1):19-26. PubMed ID: 6968190 [TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype. Lynch DH; Daynes RA; Hodes RJ J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117 [TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems. Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322 [TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxicity of activated lymphocytes on allogeneic and xenogeneic target cells. III. Species specificity of lymphocyte target cell recognition in vitro. Stejskal V; Perlmann P Eur J Immunol; 1976 May; 6(5):347-52. PubMed ID: 991906 [TBL] [Abstract][Full Text] [Related]
14. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target. Jiang H; Stewart CA; Fast DJ; Leu RW J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576 [TBL] [Abstract][Full Text] [Related]
15. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens. James SL; Lazdins JK; Hieny S; Natovitz P J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456 [TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody. Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511 [TBL] [Abstract][Full Text] [Related]
17. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats. Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719 [TBL] [Abstract][Full Text] [Related]
18. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Poste G; Kirsh R Cancer Res; 1979 Jul; 39(7 Pt 1):2582-90. PubMed ID: 87267 [TBL] [Abstract][Full Text] [Related]
19. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. Fidler IJ; Schroit AJ J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933 [TBL] [Abstract][Full Text] [Related]
20. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon. Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]